ACR Appropriateness Criteria® Movement Disorders and Neurodegenerative Diseases

, H Benjamin Harvey1, Laura C Watson2

  • 1Massachusetts General Hospital, Boston, Massachusetts.

Insights

Diagnosing movement disorders and neurodegenerative diseases is challenging due to varied symptoms. This summary provides imaging appropriateness guidelines for conditions like dementia and Parkinsonian syndromes to aid diagnosis.

Area of Science:

  • Neurology
  • Radiology
  • Medical Imaging

Background:

  • Movement disorders and neurodegenerative diseases present diagnostic challenges due to variable and overlapping symptoms.
  • Accurate diagnosis often requires a multimodal approach, including imaging, laboratory, and genetic testing.

Framework:

  • The American College of Radiology Appropriateness Criteria provide evidence-based guidelines for imaging in specific neurological conditions.
  • These guidelines are developed through rigorous literature review and expert consensus using established methodologies like RAND/UCLA and GRADE.

Implementation:

  • This document specifically addresses imaging appropriateness for rapidly progressive dementia, chorea, Parkinsonian syndromes, neurodegeneration with brain iron accumulation, and motor neuron disease.
  • MRI plays a crucial role in the initial assessment of these conditions.

Implications:

  • These guidelines aim to standardize and optimize the use of medical imaging in the evaluation of complex neurological disorders.
  • Utilizing these criteria can lead to more accurate and timely diagnoses, improving patient management and outcomes.

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.6K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
852
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
687